Novel strategies for blood stem cell mobilization: Special focus on plerixafor

Expert Opinion on Biological Therapy

Volumn 11, Issue 9, 2011, Pages 1241-1248

  Jantunen, Esa ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Blood stem cells; G CSF; Mobilization; Plerixafor

Indexed keywords

CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; PLERIXAFOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ALLOTRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; DRUG STRUCTURE; MYELOMA; NONHODGKIN LYMPHOMA; STEM CELL MOBILIZATION;

ANIMALS; ANTI-HIV AGENTS; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; LEUKEMIA; LYMPHOMA; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION;

EID: 80051542003     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.601737     Document Type: Article

References (70)

1. Gratwohl A, Baldomero H, Schwendener A, et al. The EBMT activity survey 2008: impact of team size, team density and new trends. Bone Marrow Transplant 2011;46:174-91
2. Steinberg M, Silva M. Plerixafor: a chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma. Clin Ther 2010;32:821-43
3. Pusic I, DiPersio JF. Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. Curr Opin Hematol 2010;17:319-26
4. Richman CM, Weiner RS, Yankee RA. Increase in circulating stem cells following chemotherapy in man. Blood 1976;47:1031-9
5. Stiff PJ, Murgo AJ, Wittes RE, et al. Quantification of the peripheral blood colony forming unit-culture rise following chemotherapy. Could leukocytapheresis replace bone marrow transplantation? Transfusion 1983;23:500-3 (Pubitemid 14210547)
6. Demirer T, Buckner CD, Bensinger WI. Optimization of peripheral blood stem cell mobilization. Stem Cells 1996;14:106-16 (Pubitemid 26041425)
7. Bensinger W, DiPersio JF, McCarty JM. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009;43:181-95
8. Gertz MA. Current status of stem cell mobilization. Br J Haematol 2010;150:647-62
9. Kroschinsky F, Holig K, Poppe-Thiede K, et al. Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blod progenitor cells in healthy family and unrelated donors. Haematologica 2005;90:1665-71 (Pubitemid 41814992)
10. Lemoli R, d'Addio A. Hematopoietic stem cell mobilization. Haematologica 2008;93:321-4 (Pubitemid 351398630)
11. Duchrsen U, Villeval JL, Boyd J, et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988;72:2074-81 (Pubitemid 19030905)
12. Socinski MA, Cannistra S, Elias A et al. Granulocyte-macro phage colony-stimulating factor expands the circulating haematopoietic progenitor cell compartment in man. Lancet 1988;1:1194-8
13. Hosing C, Saliba RM, Ahlawat S, et al. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 2009;84:335-7
14. Jantunen E, Kvalheim G. Mobilization strategies in hard-to-mobilize patients with lymphoid malignancies. Eur J Haematol 2010;85:463-71
15. Wuchter P, Ran D, Bruckner T, et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010;16:490-9
16. Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008;14:1045-56
17. Jantunen E, Kuittinen T. Blood stem cell mobilization and collection in patients with lymphoproliferative disease: practical issues. Eur J Haematol 2008;80:287-95 (Pubitemid 351347581)
18. De Clercq E. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers. Pharmacol Ther 2010;128:509-18
19. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003;102:2728-30 (Pubitemid 37248839)
20. Liles WC, Rodger E, Broxmeyer HE, et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005;45:295-300 (Pubitemid 40389423)
21. Lapidot T, Collet O. The-brain-bone-blood triad: traffic lights for stem cell homing and mobilization. American Society of Hematology, Education Program Book, Hematology; 2010. p. 1-6
22. Flomenberg N, Devine SN, DiPersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005;106:1867-74 (Pubitemid 41208607)
23. Stiff P, Micallef I, McCarty P, et al. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implication for the heavily treated patients. Biol Blood Marrow Transplant 2009;15:249-56
24. Cashen A, Lopez S, Gao F, et al. A Phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic stem cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant 2008;14:1253-61
25. Micallef INM, Ho AD, Klein LM, et al. Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide. Bone Marrow Transplant 2011;46:350-5
26. Mark TM, Rossi AC, Pearse RN, et al. A comparison of chemotherapy + G-CSF versus plerixafor (MozobilR) + G-CSF for stem cell mobilization in patients with multiple myeloma treated with lenalidomide. Blood 2010;116:abstract 2258
27. Basak GW, Jaksic O, Koristek Z, et al. Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells. Eur J Haematol 2011;86:488-95
28. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009;27:4767-73
29. Micallef IN, Stiff PJ, DiPersio JF, et al. Successful stem cell mobilization using plerixafor (Mozobil) plus granulocyte colony-stimulating factor in patients with non-Hodgkin lymphoma: results from the plerixafor NHL Phase 3 study rescue protocol. Biol Blood Marrow Transplant 2009;15:1578-86
30. DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009;113:5720-6
31. Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008;41:331-8 (Pubitemid 351330727)
32. Duarte R, Shaw BE, Marin P, et al. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant 2011;46:52-8
33. Apperley J, Cook G, Pagliuca A, et al. Efficacy of plerixafor plus G-CSF for stem cell mobilization in patients with multiple myeloma or lymphoma who have failed prior mobilization-named patient program evaluation [abstract 0519]. Haematologica 2010;95(Suppl 2):212
34. Hubel K, Fresen MM, Salwender H, et al. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplant 2010;published online 25 October 2010; doi:10.1038/bmt.2010.249
35. Worel N, Rooskopf K, Neumeister P, et al. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on named patient program. Transfusion 2011;51:968-75
36. Basak GW, Knopinsky-Posluzny W, Matuszak M, et al. Hematopoietic stem cell mobilization with the reversible CXCR4 receptor antagonist plerixafor (AMD3100). Ann Hematol 2011;90:488-95
37. Gabriel IH, Apperley JF, Szydlo R, et al. The role of the CXCR4 antagonist Plerixafor in elderly patients failing autologous stem cell mobilization. Data from the Plerixafor Compassionate Use Study. On behalf of the European Consortium for Stem Cell Mobilization (ECOSM) [abstract 1073]. Bone Marrow Transplant 2011;46(Suppl 1):S331-2
38. Basak G, Wiktor-Jedrzejczak W, Apperley J, et al. Autologous haematopoitic stem cell mobilization with plerixafor and G-CSF: impact of overweight and obesity [abstract 1077]. Bone Marrow Transplant 2011;46(Suppl 1):S333
39. Shenoy S, Asselin B, Dalal J, et al. Safety and efficacy of hematopoietic stem cell remobilization with plerixafor (MozobilR) + G-CSF in pediatric patients with malignant disorders [abstract 923]. Blood 2010;116:923
40. Aabideen K, Anoop P, Ethell ME, Potter MN. The feasibility of plerixafor as a second-line stem cell mobilizing agent in children. J Pediatr Hematol Oncol 2011;33:65-7
41. Modak S, Cheung IY, Kushner BH, et al. Plerixafor plus granulocyte-colony stimulating factor for autologous hematopoietic stem cell mobilization in patients with metastatic neuroblastoma. Pediatr Blood Cancer 2011;published online 17 March 2011; doi: 10.1002/pbc.23132
42. Herbert K, Demosthenous L, Wiesner G, et al. Plerixafor plus single dose pegfilgrastim for hematopoietic stem and progenitor cell mobilization: and efficient and safe regimen in good and poor mobilizers [abstract 2256]. Blood 2010;116:928
43. Dugan MJ, Maziarz RT, Bensinger WI, et al. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicentre, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010;45:39-47
44. Jantunen E, Penttila K, Pyorala M, et al. Addition of plerixafor to a chemotherapy and G-CSF mobilization in hard-to-mobilize patients. Bone Marrow Transplant 2011;46:308-9
45. d'Addio A, Curti A, Worel N, et al. The addition of plerixafor is safe and allow adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2011; 46: 356-63
46. Segel E. Sorensen B, d'Amore F, Hokland P. Successful peripheral blood stem cell harvest in mobilization-refractory lymphoma patients (abstract). Bone Marrow Transplant 2010;45(Suppl 2):S258
47. Josefsen D, Rechnitzer C, Parto K, Kvalheim G. The use of plerixafor for blood stem cell mobilization failure in patients planned to undergo autologous stem cell transplantation. Eur Haematol 2010;4:34-9
48. Basak GW, Urbanowska E, Boguradzki P, et al. Booster plerixafor can be successfully used in addition to chemotherapy-based regimen to rescue stem cell mobilization failure. Ann Transplant 2010;15:61-7
49. Jantunen E, Kuittinen T, Mahlamaki E, et al. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience. Eur J Haematol 2011;86:299-304
50. Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004;22:1095-102 (Pubitemid 41095043)
51. Flomenberg N, Comenzo R, Badel K, Calandra G. Plerixafor (Mozobil) alone to mobilize hematopoietic cells from multiple myeloma patients for autologous transplantation. Biol Blood Marrow Transplant 2010;16:695-700
52. Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100 alone, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008;112:990-8
53. Rettig MP, Lopez S, McFarland K, et al. Rapid and prolonged mobilization of human CD34+ hematopoietic stem cells following intravenous (IV) administration of plerixafor [abstract 2261]. Blood 2010;116:930
54. Douglas KW, Parker AN, Hayden PJ, et al. Plerixafor for PBSC mobilization in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and USA. Bone Marrow Transplant 2011;published online 28 February 2011; doi:10.1038/bmt.2011.9
55. DiPersio JF, Bridger G, Calandra G. Effect of plerixafor (AMD3100) plus G-CSF on tumour cell mobilization among patients with lymphoma [abstract]. Biol Blood Marrow Transplant 2009;15:37
56. Fruehauf S, Ehninger G, Hubel K, et al. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumour cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplant 2010;45:269-75
57. Morris C, Sureda A, van Biezen AM, et al. The EMA-directed plerixafor safety survey: the EBMT CALM study [abstract 244]. Bone Marrow Transplant 2011;46(Suppl 1):S32
58. Shaughnessy P, Islas-Ohlmayer M, Murphy J, et al. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Biol Blood Marrow Transplant 2011;17:729-36
59. Bodart V, Anastassov V, Darkes MC, et al. Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4. Biochem Pharmacol 2009;15:993-1000
60. Pelus LM, Fukuda S. Peripheral blood stem cell mobilization: the CXCR2 ligand GRObeta rapidly mobilizes hematopoietic stem cells with enhanced engraftment properties. Exp Hematol 2006;34:1010-20 (Pubitemid 44080384)
61. Ballen KK, Shpall EJ, Avigan D, et al. Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant 2007;13:838-43 (Pubitemid 46902439)
62. DiPersio JF. Can every patient be mobilized? Best Pract Res Clin Haematol 2010;23:519-23
63. Fruehauf S, Tricot G. Comparison of unmobilized and mobilized graft characteristics and the implications of cell subsets on autologous and allogeneic transplant outcomes. Biol Blood Marrow Transplant 2010;16:1629-48
64. Jantunen E, Fruehauf S. Importance of graft characteristics in auto-SCT: implication for optimizing mobilization regimens. Bone Marrow Transplant 2011;46:627-35
65. Gertz MA, Wolf RC, Micallef IN, Gastineau DA. Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma. Bone Marrow Transplant 2010;45:1396-403
66. Jagasia MH, Savani BN, Neff A, et al. Outcome, toxicity profile and cost analysis of autologous stem cell mobilization. Bone Marrow Transplant 2010;published online 1 November 2010; doi:10.1038/bmt.2010.254.
67. Costa LJ, Milles AN, Alexander ET, et al. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011;46:523-8
68. Costa LJ, Alexander ET, Hogan KR, et al. Development and validation of a decision making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011;46:64-9
69. Duong HK, Bolwell BJ, Rybicki L, et al. Predicting hematopoietic stem cell mobilization failure in patients with multiple myeloma: a simple method using day 1 CD34 cell yield. J Clin Apher 2011;26:111-15
70. Mohty M, Duarte RF, Crookewit S, et al. The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia 2011;25:1-6